Preclinical studies have shown that blocking programmed cell death protein-1 (PD-1) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) can significantly inhibit the growth of glioma cells and prolong the survival time of experimental animals (94). The gene discussed is CTLA4; the disease is central nervous system cancer.